CALC Stock Analysis: Buy, Sell, or Hold?
CALC - CalciMedica, Inc. Common Stock
$0.84
-0.02 (-2.10%)
▼
5d:
-9.82%
30d:
+35.48%
90d:
+2.14%
HOLD
LOW Confidence
Analysis Updated: Jun 17, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When CALC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CALC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CALC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CALC is currently trading at $0.84, which is considered fair relative to its 30-day fair value range of $0.66 to $0.91.
Technical Outlook: Technically, CALC is showing sideways momentum. Immediate support is located at $0.79, while resistance sits at $1.14.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $10.33 (+1104.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CALC is showing sideways momentum. Immediate support is located at $0.79, while resistance sits at $1.14.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (17th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $10.33 (+1104.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.66 -
$0.91
Company Quality Score
52/100
(HOLD)
Options IV Signal
17th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 17th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1104.3% below Wall St target ($10.33)
- CAUTION: Recommendation downgraded due to -9.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.66 -
$0.91
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.25
(29.4%)
Support & Resistance Levels
Support Level
$0.79
Resistance Level
$1.14
Current Trend
Sideways
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.44
Wall Street Target
$10.33
(+1104.3%)
Share & Embed Analysis
Last updated: June 17, 2026 4:16 PM ET
Data refreshes hourly during market hours. Next update: 5:16 PM
Data refreshes hourly during market hours. Next update: 5:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CALC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 66 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 54 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$256 | 58 HOLD |
